YER190C-B Antibody

What is YER190C-B and why is it important in yeast research?

YER190C-B is a gene symbol associated with Saccharomyces cerevisiae (baker's yeast), specifically identified in strain ATCC 204508. The antibody targeting this gene product is valuable for researchers investigating yeast cellular processes. YER190C-B antibodies allow for specific detection of this protein target across various experimental platforms, particularly in protein expression and localization studies. When designing experiments with this antibody, researchers should consider the protein's predicted molecular weight and expression patterns across different growth conditions to properly interpret results. Establishing appropriate positive and negative controls is essential when first implementing this antibody in your research program.

What are the primary applications for YER190C-B antibody in yeast research?

The YER190C-B antibody has demonstrated utility in multiple applications, primarily ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot (WB) techniques . For ELISA applications, this polyclonal antibody enables quantitative detection of the target protein in complex sample mixtures. When used in Western blotting, it facilitates protein identification after separation by gel electrophoresis. The polyclonal nature of this antibody (CSB-PA317849XA01SVG-10) provides recognition of multiple epitopes on the target protein, potentially increasing sensitivity compared to monoclonal alternatives. Researchers should implement appropriate blocking protocols (typically 5% non-fat milk or BSA in TBST) to minimize background signal when using this antibody in immunological applications.

What is the recommended protocol for using YER190C-B antibody in Western blot applications?

For optimal Western blot results with YER190C-B antibody, follow this methodological approach: First, extract proteins from Saccharomyces cerevisiae using established lysis buffers containing protease inhibitors. Separate proteins using SDS-PAGE (10-12% gels typically work well for yeast proteins), then transfer to PVDF or nitrocellulose membranes. Block membranes using 5% non-fat milk in TBST for 1 hour at room temperature. Dilute the YER190C-B antibody appropriately (starting with manufacturer's recommendations, typically 1:1000-1:2000) and incubate overnight at 4°C. After washing with TBST (3-5 times for 5 minutes each), apply HRP-conjugated secondary antibody (anti-rabbit, as this is a rabbit polyclonal antibody) for 1 hour at room temperature. Following additional washing steps, visualize using ECL substrate and appropriate imaging system. Optimization of antibody concentration may be necessary depending on your specific experimental conditions and protein abundance.

How should researchers troubleshoot inconsistent results when using YER190C-B antibody in different yeast strains?

Inconsistent results across yeast strains when using YER190C-B antibody likely stem from strain-specific genetic variations. Begin troubleshooting by verifying target gene expression in each strain through RT-qPCR. The antibody was developed using recombinant protein from Saccharomyces cerevisiae strain ATCC 204508 , so strains with significant genetic divergence may show altered epitope recognition. Sequence alignment analysis between your strain and ATCC 204508 can predict potential recognition issues. Experimental modifications to consider include: adjusting antibody concentration (typically testing a range from 1:500 to 1:5000), optimizing protein extraction methods for different strains (including testing different lysis buffers with varying detergent compositions), and modifying incubation times. Additionally, testing cross-reactivity with recombinant protein positive controls can validate antibody functionality. Document strain-specific protocols that yield optimal results for reproducibility.

What strategies can researchers employ to enhance specificity when using YER190C-B antibody in co-immunoprecipitation experiments?

For high-specificity co-immunoprecipitation using YER190C-B antibody, implement these methodological refinements: First, pre-clear lysates with protein A/G beads to remove proteins with non-specific affinity for beads. Use gentle lysis conditions that preserve protein-protein interactions (consider NP-40 or digitonin-based buffers at 0.5-1%). The polyclonal nature of the YER190C-B antibody may increase binding capacity but could potentially introduce non-specific interactions. To control for this, perform parallel experiments with pre-immune serum or IgG from the same species. Implement stringent washing protocols with increasing salt concentrations to remove weakly-bound contaminants while preserving specific interactions. For validation, perform reciprocal co-IPs with antibodies against suspected interaction partners and include appropriate controls such as lysates from cells where YER190C-B has been deleted or depleted. Additionally, crosslinking approaches (using DSP or formaldehyde) prior to immunoprecipitation may help capture transient interactions if standard approaches are unsuccessful.

How can researchers quantitatively assess YER190C-B protein expression using the antibody in different experimental conditions?

For quantitative assessment of YER190C-B protein expression across conditions, employ multiple complementary approaches. For ELISA-based quantification, generate a standard curve using purified recombinant YER190C-B protein at known concentrations . When using Western blot, include a loading control protein (such as PGK1 or TDH3) that remains stable across your experimental conditions, and use digital image analysis software to calculate normalized band intensities. For more precise quantification, consider using the antibody in conjunction with mass spectrometry-based approaches. Sample preparation is critical—ensure consistent cell numbers and extraction efficiency between conditions by normalizing to total protein concentration determined by Bradford or BCA assay. Technical replicates (minimum of three) and biological replicates (typically three independent experiments) are essential for statistical validation. When reporting results, present quantification with appropriate statistical analysis (typically ANOVA or t-tests with multiple testing correction) and clearly state normalization methods.

What controls should be included when validating YER190C-B antibody specificity for immunofluorescence microscopy?

Proper validation of YER190C-B antibody for immunofluorescence requires comprehensive controls. Essential negative controls include: samples from YER190C-B knockout strains, primary antibody omission, and secondary antibody-only treatments to assess auto-fluorescence and non-specific binding. Positive controls should include strains with tagged YER190C-B (such as GFP-fusion constructs) allowing visualization through both antibody-dependent and independent methods. For specificity confirmation, perform competition assays using the recombinant immunogen protein supplied with the antibody . Pre-absorption of the antibody with excess antigen should eliminate specific staining. Additionally, validate subcellular localization patterns by comparison with published data for similar yeast proteins or by co-localization with compartment-specific markers. Document all microscopy parameters including fixation methods (typically 4% paraformaldehyde), permeabilization conditions (usually 0.1% Triton X-100), blocking solution composition, antibody dilutions, and incubation times to ensure reproducibility. Analysis should incorporate both qualitative assessments and quantitative measurements of signal intensity and co-localization coefficients.

What factors should researchers consider when optimizing sample preparation for YER190C-B antibody detection in yeast extracts?

Optimizing sample preparation for YER190C-B detection requires careful consideration of multiple factors. The growth phase of yeast cultures significantly impacts protein expression—log phase typically yields different protein levels than stationary phase. The choice of lysis buffer is critical; for membrane-associated or difficult-to-extract proteins, consider testing buffers with different detergents (RIPA, NP-40, Triton X-100) at varying concentrations. Always include protease inhibitors (complete cocktail) to prevent degradation, and if phosphorylation studies are intended, add phosphatase inhibitors. Sample denaturation conditions affect epitope accessibility—for Western blotting, compare results using reducing versus non-reducing conditions and different heating temperatures (37°C, 70°C, 95°C). For native protein analysis, gentle extraction methods using glass bead disruption in non-denaturing buffers may preserve protein conformation and activity. When processing multiple samples, maintain consistent protocols including equivalent cell densities (typically normalized by OD600), identical incubation times, and identical protein quantities for immunoblotting (15-30 μg total protein per lane). Document optimization parameters methodically to establish a reproducible protocol specific to YER190C-B detection in your experimental system.

How can researchers effectively use YER190C-B antibody in chromatin immunoprecipitation (ChIP) experiments?

Adapting YER190C-B antibody for chromatin immunoprecipitation requires methodological optimization beyond standard ChIP protocols. Begin with crosslinking optimization—test both formaldehyde concentrations (typically 1-3%) and incubation times (5-20 minutes) to balance sufficient crosslinking with DNA accessibility. For yeast cells, enzymatic digestion of the cell wall prior to lysis enhances extraction efficiency. The polyclonal nature of this antibody may enhance capture of chromatin complexes, but necessitates stringent controls including IgG and no-antibody conditions. Sonication conditions require careful calibration; aim for DNA fragments between 200-500 bp, verified by agarose gel analysis. Pre-clearing lysates with protein A/G beads reduces background, while adding non-specific competitor DNA (salmon sperm DNA) and BSA to blocking solutions minimizes non-specific binding. For quantification, perform qPCR with primers targeting suspected binding regions and appropriate control regions. If the antibody performs inconsistently in ChIP, consider alternative approaches such as DamID or CUT&RUN, or creating epitope-tagged constructs of YER190C-B. Data analysis should include normalization to input DNA and statistical comparison to negative control regions, with replicate experiments (minimum three) providing statistical power.

What strategies should researchers employ when using YER190C-B antibody for studies involving post-translational modifications?

When investigating post-translational modifications (PTMs) of YER190C-B, implement these specialized approaches: First, determine if the polyclonal antibody (CSB-PA317849XA01SVG-10) was raised against a region containing potential modification sites—this information informs whether the antibody might recognize or be blocked by specific PTMs. For phosphorylation studies, compare results from samples treated with and without phosphatase inhibitors, complemented by lambda phosphatase treatment controls. For ubiquitination analysis, include proteasome inhibitors (MG132) during sample preparation. Consider using modification-specific detection methods including Phos-tag gels for phosphorylation or specialized enrichment methods prior to immunoprecipitation. When analyzing results, look for mobility shifts on Western blots that might indicate modified forms. Mass spectrometry analysis following immunoprecipitation with the YER190C-B antibody provides the most comprehensive PTM identification. For validation, generate site-specific mutants (e.g., changing potential phosphorylation sites from serine/threonine to alanine) and demonstrate loss of the modified form. Remember that the recombinant immunogen used to generate this antibody may lack PTMs present in vivo, potentially affecting recognition of heavily modified forms of the protein.

How can researchers utilize YER190C-B antibody in studying protein-protein interaction networks in Saccharomyces cerevisiae?

For comprehensive protein interaction network studies using YER190C-B antibody, implement a multi-technique strategy. Begin with traditional co-immunoprecipitation, optimizing lysis conditions to preserve interactions (typically using mild detergents like 0.5% NP-40). The polyclonal nature of the antibody provides good capacity for pulling down intact complexes. Validate interactions through reciprocal co-IPs and incorporate appropriate controls including IgG pulldowns and lysates from YER190C-B deletion strains. For detecting dynamic or weak interactions, consider in vivo crosslinking with cell-permeable crosslinkers like DSP (dithiobis(succinimidyl propionate)) prior to lysis. For higher-throughput analysis, adapt the antibody for proximity-based labeling techniques such as BioID or APEX, which identify proteins in close proximity to YER190C-B in living cells. For detailed complex analysis, combine antibody-based purification with mass spectrometry (immunoprecipitation-mass spectrometry or IP-MS). Compare interaction profiles under different cellular conditions (nutrient availability, stress responses, cell cycle stages) to identify context-dependent interactions. Network analysis software can help visualize and interpret complex datasets, identifying both direct binding partners and functional complexes. Confirm biological relevance of key interactions through genetic methods such as synthetic genetic array analysis or phenotypic studies of double mutants.

What are the most common technical challenges when using YER190C-B antibody and how can they be overcome?

Common technical challenges with YER190C-B antibody include background signals, weak detection, and inconsistent results. To address high background in Western blots, optimize blocking conditions by testing different blocking agents (5% BSA often performs better than milk for some antibodies) and extend blocking time to 2 hours. For weak signals, increase antibody concentration incrementally (starting from manufacturer's recommendation), extend primary antibody incubation (overnight at 4°C), or utilize signal enhancement systems like biotin-streptavidin amplification. If epitope masking is suspected, test different antigen retrieval methods for fixed samples or alternative protein denaturation protocols for Western blotting. For immunoprecipitation applications showing poor yield, increase starting material, optimize lysis buffer composition, or pre-couple the antibody to beads before adding lysate. When batch-to-batch variation occurs with the polyclonal antibody , normalize results to standard samples run across experiments or consider purchasing larger lots for critical research projects. If troubleshooting these parameters doesn't resolve issues, verify target protein expression in your specific yeast strain, as strain-specific variations might affect antibody performance. Document all optimization steps methodically to establish robust protocols for your specific experimental system.

How should researchers approach quantitative analysis when using YER190C-B antibody in multi-protein complex studies?

For quantitative analysis of YER190C-B in multi-protein complexes, implement rigorous methodological controls to ensure accurate measurements. Begin by establishing the antibody's dynamic range using known quantities of recombinant YER190C-B protein . For co-immunoprecipitation experiments, include spike-in controls with defined protein ratios to normalize pulldown efficiency between samples. When performing relative quantification in Western blots, use digital imaging systems rather than film for wider linear dynamic range, and utilize analysis software that corrects for background and saturation effects. For absolute quantification, consider stable isotope labeling approaches (SILAC) combined with mass spectrometry after immunoprecipitation. Control for antibody cross-reactivity by parallel analysis of YER190C-B knockout strains. For complex stoichiometry determination, compare relative abundances of co-precipitating proteins while accounting for molecular weight differences, ionization efficiencies (in mass spectrometry), or differential antibody affinities (in Western blots). Statistical analysis should incorporate both technical replicates (minimum three) and biological replicates (typically three independent experiments) with appropriate statistical tests (ANOVA with post-hoc tests for multiple conditions). Present data with clearly stated normalization methods and confidence intervals to facilitate interpretation of complex formation differences across experimental conditions.